article Open AccessTop 1% cited
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society
European Heart Journal · 2013 · Vol. 34(45) · pp. 3478–3490
Børge G. Nordestgaard✉(Herlev Hospital)M. John Chapman✉(Inserm)Steve E. Humphries(University College London)Henry N. Ginsberg(Columbia University)L. Masana(Universidad Rovira i Virgili)Olivier Descamps(Hôpital de Jolimont)Olov Wiklund(Sahlgrenska University Hospital)Robert A. Hegele(Western University)Frederick J. Raal(University of the Witwatersrand)Joep C. Defesche(Academic Medical Center)Albert Wiegman(Academic Medical Center)Rodrigo da Silva Santos(Universidade de São Paulo)Gerald F. Watts(University of Western Australia)KG Parhofer(Ludwig-Maximilians-Universität München)G. Kees Hovingh(Academic Medical Center)Petri T. Kovanen(Wihuri Research Institute)Cathérine Boileau(Inserm)Maurizio Averna(University of Palermo)Jan Borén(University of Gothenburg)E. Bruckert(Pitié-Salpêtrière Hospital)Alberico L. Catapano(MultiMedica)Jan Albert Kuivenhoven(University Medical Center Groningen)P. Pajukanta(University of California, Los Angeles)Kausik K. Ray(St George's, University of London)A.F.H. Stalenhoef(Radboud University Medical Center)Erik S.G. Stroes(Academic Medical Center)Marja‐Riitta Taskinen(Wihuri Research Institute)Anne Tybjærg‐Hansen(University of Copenhagen)for the European Atherosclerosis Society Consensus Panel
Abstract
Owing to severe underdiagnosis and undertreatment of FH, there is an urgent worldwide need for diagnostic screening together with early and aggressive treatment of this extremely high-risk condition.
Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and LipoproteinsCancer, Lipids, and MetabolismMedicineCoronary heart diseaseStatement (logic)PopulationIntensive care medicineConsensus conferenceDiseaseAtherosclerotic cardiovascular diseaseInternal medicineCardiology
MeSH terms
AdultAnticholesteremic AgentsChildChild, PreschoolCoronary DiseaseCost-Benefit AnalysisDelivery of Health CareFemaleForecastingHeterozygoteHomozygoteHumansHyperlipoproteinemia Type IICholesterol, LDLMale
Funding
- Amgen
- AstraZeneca
- Sanofi
- F. Hoffmann-La Roche
- Regeneron Pharmaceuticals
- Kowa Company
Citations
2,699
FWCI
161.84
field-weighted impact
References
57
Percentile
100%
vs. same field & year
Citations per year
Cited by
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Atherosclerosis · 2016 · 1,581 citations
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
European Heart Journal · 2016 · 3,169 citations
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Circulation · 2019 · 8,933 citations
2016 European Guidelines on cardiovascular disease prevention in clinical practice
European Heart Journal · 2016 · 6,439 citations
Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation
International Journal of Cardiology · 2013 · 374 citations
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Circulation · 2020 · 9,238 citations
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Atherosclerosis · 2016 · 484 citations
References
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
European Heart Journal · 2011 · 3,538 citations
Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia
Atherosclerosis · 2004 · 495 citations
PCSK9: a convertase that coordinates LDL catabolism
Journal of Lipid Research · 2008 · 625 citations
A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia
Atherosclerosis · 2003 · 566 citations
Lipoprotein(a) as a cardiovascular risk factor: current status
European Heart Journal · 2010 · 1,758 citations
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
The Lancet · 2010 · 6,335 citations
European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts)
European Heart Journal · 2007 · 3,753 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.